The debut of a new GLP-1 analog used as an adjuvant to dietary and exercise therapy in diabetes patients has been postponed in Korea.

This comes as a disappointment as only one single-agent drug is currently reimbursed in Korea, and the high global demand for the drugs has rendered domestic supply short.

According to the Health Insurance Review and Assessment Service and the industry on the 1st, discussions for the reimbursement of Novo Nordisk’s single agent GLP-1 receptor agonist ‘Ozempic Pre-Filled Pen' have come to a stop.

This drug was recognized as appropriate for reimbursement by the Drug Reimbursement Evaluation Committee in February under the condition that th